The FTC has informed Germany-based Fresenius Medical Care that it can complete its $3.5 billion acquisition of Renal Care Group, which operates 450 hemodialysis centers in the U.S. Last year the FTC took issue with the buyout, say that the combined entity would effectively become a monopoly in 66 markets around the nation. These are markets in which Fresenius and RCG had been competitors. The buyout would essentially end competition in these areas. As part of the settlement, Fresenius must sell over 100 centers to National Renal Institutes.
- read the FTC's announcement on the approval of the final consent order
PLUS: Renal Advantage has purchased seven dialysis clinics in Virginia. Release